<SEC-DOCUMENT>0000950170-25-072872-index.html : 20250515
<SEC-HEADER>0000950170-25-072872.hdr.sgml : 20250515
<ACCEPTANCE-DATETIME>20250515172636
ACCESSION NUMBER:		0000950170-25-072872
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250515
DATE AS OF CHANGE:		20250515

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-85205
		FILM NUMBER:		25955978

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ikarian Capital, LLC
		CENTRAL INDEX KEY:			0001778253
		ORGANIZATION NAME:           	
		EIN:				473466768
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		100 CRESCENT COURT
		STREET 2:		SUITE 1620
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201
		BUSINESS PHONE:		214-364-2883

	MAIL ADDRESS:	
		STREET 1:		100 CRESCENT COURT
		STREET 2:		SUITE 1620
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
Document 1 - file: primary_doc.html

Document 1 - RAW XML: primary_doc.xml

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ck0001669811-ex99_1.pdf
<DESCRIPTION>EX-99.1
<TEXT>
Document 2 - file: ck0001669811-ex99_1.pdf

</DOCUMENT>
</SEC-DOCUMENT>